Categories: Health

Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting

 | Source: Aurora Spine Corporation

Company to Showcase Cutting-Edge Innovations at Booth #1622 

CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its participation at the 2025 North American Spine Society (“NASS”) Annual Meeting. The event will take place from November 14-16, 2025, at the Colorado Convention Center, in Denver, Colorado. Aurora Spine will be exhibiting at Booth #1622. 

The North American Spine Society is a global multidisciplinary medical society that utilizes education, research, and advocacy to foster the highest quality, ethical, and evidence-based spine care.  NASS gathers spine professionals from around the world, offering a unique platform for Aurora to showcase its latest innovations.

At this year’s event, the company will feature its newly launched Hydra ANATOMIC. ELEVATED. RIGID. OSTEOFIXATION Facet Fusion System for facet joint-related pain or instability and DEXA-L, a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures, which is part of Aurora’s patented DEXA™ Technology Platform, which offers patient-matched implants designed to align with individual bone density and T-Score, ushering in a new era of personalized spinal care.

“We are excited to attend NASS 2025 and to showcase our cutting-edge, proprietary products we’ve developed, especially the recently launched Hydra and DEXA-L product lines,” said Trent Northcutt, President and CEO of Aurora Spine. “We’ve worked diligently to bring new, proprietary technologies to market that are transforming spinal surgery, and we can’t wait to share them with the industry at NASS 2025.”

Laszlo Garamszegi, Chief Technology Officer, added: “We’re particularly excited to showcase the DEXA-L implant line, which is the first of its kind in the world and is the first spinal implant that is a bone-mimicking™ structural implant helping doctors match the implant to the patient’s bone density and quality. These products are game-changing for spine surgeons and their patients, and we are proud to be presenting them at NASS 2025 and connecting with industry professionals in attendance.”

Visit Aurora Spine at Booth #1622 to witness live demonstrations and engage with the team on how these innovations are reshaping spinal surgery.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Clouse

Chief Financial Officer

(760) 424-2004

www.aurora-spine.com

Investor Relations

Adam Lowensteiner

Lytham Partners

Phone: (646) 829-9702

Email: asapf@lythampartners.com

GlobeNews Wire

Recent Posts

Blockchain.com Unveils Highly Anticipated Crypto-Backed Loans, Bringing Borrowing To Crypto Holders Worldwide

The company launches in-house lending for global users starting at 1.9%, delivering one of the…

41 minutes ago

Artmarket.com: The Artprice Manifesto: 22 Rules for a Regulated and Transparent Art Market in the Age of AI

Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS, May 14, 2026…

41 minutes ago

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

10 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

10 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

10 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

10 hours ago